Clinical pearl! Dr. Winthrop holds JAKi for one week after vaccination. #RNL2024 @RheumNow https://t.co/BLiKu8xX7t

Dr. Strober's JAKi in dermatology takeaways! - Consider this for AD - Dose matters in terms of both efficacy and toxicity - Consider combination tx - Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas) #RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz

JAKi are being used in inflammatory skin disease other than psoriasis: #HydradenitisSuppurativa, #alopecia, #AtopicDermatitis and #vitiligo - Dr. B Strober #RNL2024 @rheumnow https://t.co/FzPyATPB93

Povorcitinib - JAK1 specific for Hidradenitis Suppurativa Efficacy at 16 weeks, improvement of disease and draining tunnel count over PBO Upadacitinib shown with benefit for HS, but not as dramatic JAK response as other derm conditions #RNL2024 @RheumNow https://t.co/f2cxJbLi1I

Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE

Impressive results for alopecia totalis with baricitinib – Dr. Bruce Strober #RNL2024 @rheumnow https://t.co/OA0tpdRum2

Clinical pearl! Consider topical ruxolitinib for your AD patients. Dr. Strober at #RNL2024 @RheumNow https://t.co/Sxwvn1lAXB

Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx

♀️ ♂️Sex Matters in Psoriatic Arthritis👉 Pleasure to discuss how to consider sex/gender in the management of PsA @RheumNow #RNL24 Dallas https://t.co/RRgzudZV0S